Trials / Active Not Recruiting
Active Not RecruitingNCT06568887
Effectiveness of 5% Dextrose Water Versus Corticosteroid Injection for Pain Management of SJD
Effectiveness of 5% Dextrose Water (D/W) Versus Corticosteroid Injection for Pain Management of Sacroiliac Joint Dysfuntion
- Status
- Active Not Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 120 (actual)
- Sponsor
- Superior University · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The sacroiliac joint (SIJ) is identified as a potential origin of low back pain and referred pain to the lower limb, with a prevalence rate ranging from 7% to 30%. Typically, SIJ pain manifests in the buttock and occasionally extends to the posterior aspect of the ipsilateral thigh, resembling pain originating from lumbar spine sources, such as the zygapophysial joints or intervertebral discs.
Detailed description
For Sacroiliac Joint Dysfunction (SIJD) by examining the comparative effectiveness of two distinct interventions: the innovative 5% Dextrous Water (D/W) solution and the conventional corticosteroid injection. With corticosteroids associated with well-documented side effects and concerns about long-term use, the exploration of 5% D/W is particularly timely and holds promise as a potentially safer alternative.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| COMBINATION_PRODUCT | Dextrose Water | Individuals in this group will receive three injections of 5% dextrose water per week for six weeks period to treat their pain in sacroiliac joint and then their responce will b documented. |
| COMBINATION_PRODUCT | Corticosteroid Injection | Individuals in this group will receive three corticosteroid injections per week for a period of six weeks to treat their pain in Sacroiliac joint and then their responce will also be documented. |
Timeline
- Start date
- 2023-10-30
- Primary completion
- 2024-05-01
- Completion
- 2024-09-30
- First posted
- 2024-08-23
- Last updated
- 2024-08-23
Locations
1 site across 1 country: Pakistan
Source: ClinicalTrials.gov record NCT06568887. Inclusion in this directory is not an endorsement.